Table 1 Characteristics of LEOSS and UKD patients with CP treatment.

From: Convalescent plasma treatment for SARS-CoV-2 infected high-risk patients: a matched pair analysis to the LEOSS cohort

Variable

Nr patients

Mortality (n/% out of category)

LEOSS

UKD

LEOSS

UKD

Total

156

55

46

23

Age

18–25 years

3

1

0

0

26–35 years

6

1

0

0

36–45 years

12

5

2 (16.7)

0

46–55 years

32

3

6 (18.8)

3 (100)

56–65 years

36

13

11 (30.1)

4 (30.7)

66–75 years

36

15

14 (38.9)

10 (66.7)

76–85 years

25

9

11 (44)

3 (33.3)

 > 85 years

6

8

2 (33.3)

3 (37.5)

Gender

Male

119

34

40 (33.6)

16 (47)

Female

37

21

6 (16.7)

7 (33.3)

BMI

18,5–24,9 kg/m2

35

18

7 (20)

9 (50)

25–29,9 kg/m2

47

18

17 (36.2)

7 (38.9)

30–34,9 kg/m2

31

8

11 (35.5)

2 (25)

 > 34,9 kg/m2

14

5

5 (35.7)

3 (60)

Unknown

29

6

6 (20.7)

2 (33.3)

Stage at diagnosis

Uncomplicated phase

81

14

17 (21)

3 (21.4)

Complicated Phase

45

18

15 (33.3)

6 (33.3)

Critical illness

29

23

14 (48.3)

14 (60.8)

Unknown

1

 

0

 

Duration inpatient stay

 ≥ 14 days

119

36

35 (29.4)

14 (38.9)

 < 14 days

36

19

10 (27.8)

9 (47.4)

Missing

1

 

1 (100)

 

Duration ICU stay

 < 3

31

2

5 (16.1)

1 (50)

3–15

37

20

15 (40.5)

12 (60)

 > 15 days

77

14

26 (33.8)

7 (50)

Missing

11

 

0

 

None

 

19

 

3 (15.8)